Graphite Bio leads this week's IPO squad, look­ing to turn the tide on sick­le cell dis­ease with gene edit­ing

Ed­i­tor’s note: In­ter­est­ed in fol­low­ing bio­phar­ma’s fast-paced IPO mar­ket? You can book­mark our IPO Track­er here.

Biotech’s IPO march con­tin­ued ear­li­er this week with Monte Rosa pric­ing on Thurs­day, and now Fri­day’s bunch heads to Nas­daq led by gene edit­ing play­er Graphite Bio.

Lo­cat­ed in South San Fran­cis­co, Graphite is go­ing pub­lic Fri­day on the heels of a $238 mil­lion raise less than 10 months af­ter get­ting start­ed with a Se­ries A. It’s been a rapid as­cent, CEO Josh Lehrer told End­points News, but he feels the com­pa­ny is now at the point where it can fo­cus both on drug de­vel­op­ment and fur­ther build­ing out its plat­form.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER